Thymol Supply Agreement For Bee Health

10 April 2025

Eden Research plc

("Eden" or "the Company")

Agreement to supply thymol for bee health applications in the United States

Eden Research plc (AIM: EDEN), a leader in sustainable biopesticide and biocontrol technology, is pleased to announce that it has signed an agreement with Véto-pharma, a French pharmaceutical laboratory specialising in animal health, to supply thymol for use in bee care products.

Thymol is a naturally occurring bioactive molecule found in the essential oil of several plants, including thyme, oregano and sage. It is widely used across the pharmaceutical, agricultural, consumer product, and industrial sectors due to its antimicrobial, antifungal and aromatic properties.

Thymol is one of the three active ingredients in Eden's suite of biopesticide products and is currently registered in the EU and US. Thymol will be used in one of Véto-pharma's bee care products, a varroa mite treatment for bee hives.

Sean Smith, Chief Executive Officer of Eden Research, commented:

"We are always looking for opportunities to leverage our existing registrations and technologies to diversify our product portfolio and revenue streams. This represents a meaningful contribution to that strategy, while also enhancing the return on investments made in active ingredient dossiers across the EU, the US, and other markets.

We are pleased to be working with our new partner, Véto-pharma and supporting them in making their product a great success. We anticipate there will be additional opportunities in the future to further expand this relationship."

-- ENDS --

For further information contact:

Notes to Editors:

Eden Research is the only UK-listed company focused on biopesticides for sustainable agriculture. It develops and supplies innovative biopesticide products and natural microencapsulation technologies to the global crop protection, animal health and consumer products industries.

Eden's products are formulated with terpene active ingredients, based on natural plant defence metabolites. To date, they have been primarily used on high-value fruits and vegetables, improving crop yields and marketability, with equal or better performance when compared with conventional pesticides. Eden has three products currently on the market:

Based on plant-derived active ingredients, Mevalone® is a foliar biofungicide which initially targets a key disease affecting grapes and other high-value fruit and vegetable crops. It is a useful tool in crop defence programmes and is aligned with the requirements of integrated pest management programmes. It is approved for sale in a number of key countries whilst Eden and its partners pursue regulatory clearance in new territories thereby growing Eden's addressable market globally.

Novellus®+ is an evolution of Mevalone, allowing improved rates in the field, high levels of efficacy and a broader list of targets.

Cedroz™ is a bionematicide that targets free living nematodes which are parasitic worms that affect a wide range of high-value fruit and vegetable crops globally. Cedroz is registered for sale on two continents and Eden's commercial collaborator, Eastman Chemical, is pursuing registration and commercialisation of this important new product in numerous countries globally.

Eden's seed treatment product, Ecovelex™ was developed to safely tackle crop destruction caused by birds - a major cause of losses in maize and other crops. Ecovelex works by creating an unpleasant taste or odour that repels birds, leaving the seeds safely intact and the birds unaffected and free to find alternative food sources. The product is based on Eden's plant-derived chemistry, registered in the EU, US and elsewhere, and formulated using Eden's Sustaine® microencapsulation system.

Eden's Sustaine® encapsulation technology is used to harness the biocidal efficacy of naturally occurring chemicals produced by plants (terpenes) and can also be used with both natural and synthetic compounds to enhance their performance and ease of use. Sustaine microcapsules are naturally-derived, plastic-free, biodegradable micro-spheres derived from yeast. It is one of the only viable, proven and immediately registerable solutions to the microplastics problem in formulations requiring encapsulation.

Eden was admitted to trading on AIM on 11 May 2012 and trades under the symbol EDEN. It was awarded the London Stock Exchange Green Economy Mark in January 2021, which recognises London-listed companies that derive over 50% of their total annual revenue from products and services that contribute to the global green economy. Eden derives 100% of its total annual revenues from sustainable products and services.

For more information about Eden, please visit: www.edenresearch.com. You can also follow Eden's latest developments via its social media channels: X (Twitter) and LinkedIn.

About Véto-pharma:

Founded in 1982, Véto-pharma is a French pharmaceutical laboratory specialising in animal health, with its own dedicated research centre focused on bee health.

Present internationally, Véto-pharma employs nearly 90 people across three continents and works with a network of distributors in over 35 countries worldwide.